Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda ...

Rhenium and technetium not only share the same group in the periodic table, but also have some common history relating to how they were — or indeed weren't — discovered. Eric Scerri explains.

On Monday, BWX Technologies announced a signed purchase agreement to acquire L3Harris Technologies' Aerojet Ordnance ...

Northern Dynasty Minerals (NYSEAMERICAN:NAK – Free Report) (TSE:NDM) had its price objective raised by HC Wainwright from $0.80 to $1.30 in a report issued on Wednesday morning,Benzinga reports. HC ...

They conducted the first trial using cobalt as the catalyst and then replaced it with rhenium. The former produced methanol with an improved current density, while the latter demonstrated more ...

Nuclear fusion could be an ideal solution to mankind's energy problem, guaranteeing a virtually limitless source of power ...

In another approach, the catalyst was changed from cobalt to rhenium after being integrated into nanoporous silicon. The ...

In the search for new materials to be used in space environments, researchers are focusing on the crystallization of ...

Control of pain in patients with advanced malignancies due to bone metastases poses a challenge. Rhenium-188-hydroxyethylidine diphosphonate (188Re-HEDP) is a novel and attractive radiopharmaceutical ...

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development ...

德克萨斯州奥斯汀 - 临床阶段制药公司Plus Therapeutics, Inc. (NASDAQ:PSTV)与放射性药物合同开发和制造商SpectronRx合作,生产用于中枢神经系统 (CNS)癌症的先进放射疗法。今天宣布的制造服务协议 (MSA)聚焦于Rhenium (186Re) Obisbemeda,该疗法旨在治疗CNS癌症,包括脑膜转移和复发性胶质母细胞瘤。

Plus Therapeutics (PSTV) and SpectronRx announced the signing of a Manufacturing Services Agreement, MSA, for the production of Rhenium ...